Maxheal Pharmaceuticals (india) Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Maxheal Pharmaceuticals (india) Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $1.7M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Maxheal Pharmaceuticals (india) Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $1.7M Trade | TransData Nexus

Maxheal Pharmaceuticals (india) Limited

Indian Pharmaceutical Exporter · Antibiotics Specialist · $1.7M Total Trade · DGFT Verified

Maxheal Pharmaceuticals (india) Limited is an Indian pharmaceutical exporter with a total trade value of $1.7M across 2 products in 2 therapeutic categories. Based on 41 verified export shipments from Indian Customs (DGFT) records, Maxheal Pharmaceuticals (india) Limited is the #1 Indian exporter in 1 product including Ampicillin. Top exports include Ampicillin ($1.4M), Flucloxacillin ($314.5K), .

Maxheal Pharmaceuticals (india) Limited — Export Portfolio & Destination Treemap

Maxheal Pharmaceuticals (india) Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Maxheal Pharmaceuticals (india) Limited? — Company Overview & Market Position

Maxheal Pharmaceuticals (India) Limited, established in 1984, is a prominent pharmaceutical manufacturer and exporter based in Mumbai, Maharashtra, India. The company specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Its product portfolio encompasses a wide range of therapeutic categories such as antibiotics, anti-inflammatory agents, and central nervous system (CNS) drugs. Maxheal Pharmaceuticals is recognized for its commitment to quality and innovation, adhering to international standards in its manufacturing processes.

The company's Corporate Identification Number (CIN) is U73100MH2009PLC193624, and it is registered under the Registrar of Companies, Mumbai. Maxheal Pharmaceuticals operates as a public limited company with an authorized capital of ₹4.00 crore and a paid-up capital of ₹1.00 crore. As of the latest available data, the company employs approximately 67 professionals. The registered office is located at 301, 3rd Floor, Maxheal House, Plot No. CST No. 1043, Bangur Nagar, Goregaon (West), Mumbai, Maharashtra, 400090.

What Does Maxheal Pharmaceuticals (india) Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ampicillin$1.4M

Product Portfolio — Top 2 by Export Value

Maxheal Pharmaceuticals (india) Limited exports 2 pharmaceutical products across 2 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ampicillin	Antibiotics	$1.4M	28	1.0%	1
2	Flucloxacillin	Advanced Antibiotics	$314.5K	13	0.8%	14

Maxheal Pharmaceuticals (india) Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $1.7M. The company is the #1 Indian exporter in 1 product: Ampicillin. The top category is Antibiotics (81.7% of portfolio), followed by Advanced Antibiotics (18.3%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Maxheal Pharmaceuticals (india) Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Maxheal Pharmaceuticals operates multiple manufacturing facilities across India, each specializing in different product lines to meet diverse market demands. The company's flagship plant is situated in Nashik, Maharashtra, approximately 180 km from Mumbai. This facility is dedicated to the production of β-lactam antibiotics, including penicillins and cephalosporins, and is certified by the European Union's Good Manufacturing Practice (EU-GMP). The Nashik plant has an annual manufacturing capacity of 750 million tablets, 900 million capsules, and 5.4 million dry syrup bottles.

In addition to the Nashik plant, Maxheal Pharmaceuticals has a WHO-cGMP-certified unit in Boisar, Maharashtra, acquired from Ally Pharma Options Pvt. Ltd. This facility is approved by regulatory bodies such as NAFDAC, FDB (Ghana), Kenya, and Uganda. The Boisar plant spans 8,361 square meters, with 4,089 square meters of constructed area and an additional 4,022 square meters allocated for future expansion. This strategic location and infrastructure enable Maxheal Pharmaceuticals to cater to both domestic and international markets effectively.

3Key Leadership

Maxheal Pharmaceuticals is led by a team of experienced professionals committed to driving the company's growth and maintaining its reputation for quality. The Managing Director is Mr. Mehul Madan Sakhala, who holds a Master's degree in Management and International Business from the UK. Under his leadership, the company has implemented ultramodern technological advancements and aligned operations towards environmental sustainability.

The Board of Directors includes Mr. Madanlal Mohanlal Sakhala and Mrs. Hemlata Madanlal Sakhala, who have been instrumental in the company's strategic direction and expansion. Their combined expertise and vision have been pivotal in establishing Maxheal Pharmaceuticals as a leader in the pharmaceutical manufacturing sector.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Maxheal Pharmaceuticals (india) Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Maxheal Pharmaceuticals has made significant strides in expanding its presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's commitment to quality is evident through its adherence to international standards, as demonstrated by its EU-GMP certification for the Nashik plant. This certification facilitates access to European markets, ensuring that Maxheal Pharmaceuticals' products meet stringent quality requirements.

While specific details regarding regulatory filings and approvals in the United States, United Kingdom, Australia, and Japan are not publicly disclosed, the company's WHO-cGMP certification for the Boisar plant indicates compliance with global manufacturing standards. This certification is recognized by various international regulatory bodies, enhancing the company's credibility and potential for market access in these regions.

2Emerging Markets

Maxheal Pharmaceuticals has strategically positioned itself to penetrate emerging markets in Africa, Latin America, and Southeast Asia. The WHO-cGMP certification of its manufacturing facilities, particularly the Boisar plant, plays a crucial role in this expansion. This certification is recognized by regulatory authorities in several countries, including those in Africa and Southeast Asia, facilitating smoother market entry and acceptance.

The company's focus on quality and compliance with international standards enhances its competitiveness in these regions, where there is a growing demand for affordable and effective pharmaceutical products. By leveraging its manufacturing capabilities and certifications, Maxheal Pharmaceuticals aims to establish a strong foothold in these emerging markets, contributing to improved healthcare outcomes.

Maxheal Pharmaceuticals (india) Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Maxheal Pharmaceuticals' interactions with the U.S. Food and Drug Administration (FDA), including facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history, are not publicly disclosed. The company's adherence to international manufacturing standards, such as EU-GMP and WHO-cGMP certifications, indicates a commitment to quality that aligns with FDA expectations. However, without explicit FDA approvals or registrations, the company's direct market access in the United States remains unverified.

2WHO & EU GMP

Maxheal Pharmaceuticals' manufacturing facilities, particularly the Nashik plant, are certified by the European Union's Good Manufacturing Practice (EU-GMP). This certification ensures that the company's products meet stringent quality standards required for the European market. Additionally, the Boisar plant holds WHO-cGMP certification, recognized by various international regulatory bodies, facilitating market access in regions that acknowledge this certification.

3CDSCO & Indian Regulatory

Maxheal Pharmaceuticals (india) Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Maxheal Pharmaceuticals operates in a competitive landscape, with several key players in the Indian pharmaceutical manufacturing sector. While specific market share data is not publicly available, the company's focus on high-quality finished pharmaceutical formulations positions it favorably against competitors. The adherence to international manufacturing standards, such as EU-GMP and WHO-cGMP certifications, enhances its credibility and appeal in both domestic and international markets.

The company's strategic diversification into emerging markets further strengthens its competitive position, allowing it to tap into growing demand for affordable and effective pharmaceutical products. By leveraging its manufacturing capabilities and certifications, Maxheal Pharmaceuticals aims to establish a strong foothold in these regions, contributing to improved healthcare outcomes.

2Key Differentiators

Maxheal Pharmaceuticals distinguishes itself through its commitment to quality and innovation. The company's adherence to international manufacturing standards, as evidenced by its EU-GMP and WHO-cGMP certifications, ensures that its products meet stringent quality requirements. This focus on quality is further supported by its dedicated research and development efforts, leading to a diverse product portfolio that addresses various therapeutic areas.

Additionally, the company's strategic diversification into both regulated and emerging markets demonstrates a proactive approach to global expansion. By leveraging its manufacturing capabilities and certifications, Maxheal Pharmaceuticals aims to establish a strong foothold in

Frequently Asked Questions — Maxheal Pharmaceuticals (india) Limited

How many pharmaceutical products does Maxheal Pharmaceuticals (india) Limited export from India?

Maxheal Pharmaceuticals (india) Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Ampicillin ($1.4M), Flucloxacillin ($314.5K). Total export value is $1.7M.

What is Maxheal Pharmaceuticals (india) Limited's total pharmaceutical export value?

Maxheal Pharmaceuticals (india) Limited's total pharmaceutical export value is $1.7M, based on 41 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Maxheal Pharmaceuticals (india) Limited the #1 Indian exporter?

Maxheal Pharmaceuticals (india) Limited is the #1 Indian exporter in 1 products: Ampicillin (1.0% market share).

What therapeutic categories does Maxheal Pharmaceuticals (india) Limited cover?

Maxheal Pharmaceuticals (india) Limited exports across 2 therapeutic categories. The largest are Antibiotics (81.7%, 1 products), Advanced Antibiotics (18.3%, 1 products).

Get Full Maxheal Pharmaceuticals (india) Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.